Broadly-neutralizing anti-HIV antibodies

Patent metadata

Field	Value
Publication number	US-11142564-B2
Application number	US-201916507867-A
Country	US
Kind code	B2
Filing date	Jul 10, 2019
Priority date	Oct 18, 2012
Publication date	Oct 12, 2021
Grant date	Oct 12, 2021

Abstract

The present invention relates to anti-HW antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immuno suppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

First claim

The invention claimed is:

1. An isolated anti-HIV antibody, or antigen binding portion thereof, comprising (i) a heavy chain region that comprises CDRH 1, CDRH 2, CDRH 3 and (ii) a light chain region that comprises CDRL 1, CDRL 2 and CDRL 3, wherein said CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2, and CDRL 3 comprise the sequences of SEQ ID NOs: 57-62, respectively.

2. The isolated anti-HIV antibody of claim 1 , or antigen binding portion thereof, wherein the heavy chain region comprises the sequence of SEQ ID NO: 9.

3. The isolated anti-HIV antibody of claim 1 , or antigen binding portion thereof, wherein the light chain region comprises the sequence of SEQ ID NO: 10.

4. The isolated anti-HIV antibody of claim 3 , or antigen binding portion thereof, wherein the heavy chain region and the light chain region comprise the respective sequences of SEQ ID NOs: 9-10.

5. The isolated anti-HIV antibody of claim 1 , or antigen binding portion thereof, wherein the antibody is 10-847.

6. The isolated anti-HIV antibody of claim 1 , or antigen binding portion thereof, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

7. A pharmaceutical composition comprising (i) at least one anti-HIV antibody of claim 1 , or antigen binding portion thereof, and (ii) a pharmaceutically acceptable carrier.

8. A method of preventing or treating an HIV infection or an HIV-related disease comprising the steps of:
identifying a patient in need of such prevention or treatment, and
administering to said patient a first therapeutic agent comprising a therapeutically effective amount of at least one anti-HIV antibody of claim 1 , or antigen binding portion thereof.

9. A method for making an anti-HIV antibody or a fragment thereof, comprising obtaining a cultured cell comprising one or more nucleic acid sequences encoding the heavy chain variable region and the light chain variable region of the anti-HIV antibody of claim 1 , or antigen binding portion thereof;
culturing the cell in a medium under conditions permitting expression of the heavy chain variable region and the light chain variable region and assembling of an antibody or fragment thereof, and
purifying the antibody or fragment from the cultured cell or the medium of the cell.

10. A kit comprising
a pharmaceutically acceptable dose unit of a pharmaceutically effective amount of at least one isolated anti-HIV antibody according to claim 1 , and
a pharmaceutically acceptable dose unit of a pharmaceutically effective amount of an anti-HIV agent,
wherein the two pharmaceutically acceptable dose units can optionally take the form of a single pharmaceutically acceptable dose unit.

11. A method of reducing HIV-1 viremia in a subject, comprising administering to the subject an effective amount of the antibody of claim 1 , or antigen binding portion thereof.

12. A method of inhibiting HIV-1 viremia in a subject, comprising administering to the subject an effective amount of the antibody of claim 1 , or antigen binding portion thereof.

Assignees

• The Rockefeller Universtiy
• California Inst Of Techn
• Univ Rockefeller

Inventors

• Mouquet Hugo
• Nussenzweig Michel
• Bjorkman Pamela J
• Scharf Louise

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N2740/16111

  concerning HIV env · CPC title

• A61P31/18 Primary

  for HIV · CPC title